Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed or Refractory B-cell Lymphoma
NCT06045585Phase 1Recruiting
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell lymphoma, sponsored by Guangdong Second Provincial General Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Aug 2023; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT06045585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045585.